NHS England and NHS Improvement mandate adoption of AI-powered HeartFlow Analysis to fight coronary heart disease

Over 350 New York Auctions End Tomorrow 02/26 - Bid Now
Over 800 Total Lots Up For Auction at Two Locations - NJ Cleansweep 03/02, CA 03/12

NHS England and NHS Improvement mandate adoption of AI-powered HeartFlow Analysis to fight coronary heart disease

Press releases may be edited for formatting or style | January 27, 2021 Artificial Intelligence Cardiology
REDWOOD CITY, Calif.--(BUSINESS WIRE)--HeartFlow, Inc., a leader in revolutionizing precision heartcare, today announced that the National Health Service England (NHSE) and NHS Improvement have mandated that English hospitals adopt the AI-powered HeartFlow FFRct Analysis to fight coronary heart disease (CHD), the leading cause of death in the UK.

The HeartFlow Analysis has been selected as one of the innovations supported by NHSE’s new MedTech Funding Mandate. The Mandate, which will begin 01 April 2021, aims to provide innovative medical devices and digital products to NHSE patients faster, and is a key policy in helping to improve patient care and reduce costs for the public health service. The Mandate includes the option to extend funding for up to an additional three years through 31 March 2024.

The news comes as HeartFlow announced it also has received extended funding through NHSE’s Innovation and Technology Payment Programme (ITP) for a third year. The programme seeks to accelerate the uptake of innovations in the health service by removing financial barriers, with funding available until 31 March 2021.

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

The HeartFlow Analysis streamlines the diagnostic experience for patients – often eliminating invasive diagnostic procedures for those who do not need them. It also helps ensure those who do need invasive procedures are swiftly and accurately diagnosed. The technology limits redundant non-invasive diagnostic testing, reduces patient time in hospital and face-to-face clinical contact, and helps ensure that hospital visits for those who do need them are streamlined, which is particularly crucial during the Covid-19 pandemic.

The HeartFlow Analysis takes data from a coronary CT angiography (CTA) scan and uses deep learning technology and highly trained analysts to create a personalised, digital 3D model of the patient’s coronary arteries. Its algorithms solve millions of equations to simulate blood flow in a patient’s arteries to help clinicians assess the functional impact of any blockages.

The National Institute of Health and Care Excellence (NICE) advocates a CTA-first approach to diagnosing CHD. The HeartFlow Analysis has been declared a best practice non-invasive option for patients in recent updates to NICE’s guidance, stating that the technology should be considered as an option for patients with stable, recent onset chest pain who are offered CTA. HeartFlow plays a central role in providing clinicians greater confidence in their diagnoses, while reducing the time to diagnosis for patients.

You Must Be Logged In To Post A Comment